Vogliviga GM2/0.3 Tablet in PCD pharma franchise in Hyderabad

Vogliviga GM2/0.3 Tablet in pharmaceutical manufacturing company in Mumbai

Vogliviga GM2/0.3 Tablet in diabetic pharma franchise in Pune

Vogliviga GM2/0.3 Tablet in pharma suppliers in Delhi

Vogliviga GM2/0.3 Tablet in pharma export companies in Kolkata
Vogliviga GM2/0.3 Tablet in pharma franchise opportunities in Bengaluru

Home/Products /glimepride-i-point-p-point-2mg-voglibose-500mg-layered-tablets

Vogliviga GM 2-0.3 Tablet

Composition : Glimepiride I.P. 2mg + Voglibose I.P. 0.3mg + Metformin HCL I.P. 500mg (S.R.) Bi-Layered Tablets

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*15

Price : ₹193.5/-

Vogliviga GM2/0.3 Tablet combines Glimepiride 2mg, Voglibose 0.3mg, and Metformin 500mg (Sustained Release) in a bi-layered tablet designed for effective management of type 2 diabetes mellitus. Glimepiride stimulates insulin secretion to lower blood sugar levels, Voglibose delays carbohydrate absorption to reduce post-meal glucose spikes, and sustained-release Metformin improves insulin sensitivity while reducing glucose production in the liver. This multi-action formulation helps maintain balanced blood glucose levels throughout the day.

Read More

About the Product

Vogliviga GM2/0.3 Tablet combines Glimepiride 2mg, Voglibose 0.3mg, and Metformin 500mg (Sustained Release) in a bi-layered tablet designed for effective management of type 2 diabetes mellitus. Glimepiride stimulates insulin secretion to lower blood sugar levels, Voglibose delays carbohydrate absorption to reduce post-meal glucose spikes, and sustained-release Metformin improves insulin sensitivity while reducing glucose production in the liver. This multi-action formulation helps maintain balanced blood glucose levels throughout the day.

Common side effects may include gastrointestinal discomfort such as nausea, abdominal pain, bloating, and diarrhea. Hypoglycemia can occur, particularly if meals are missed or dosing is incorrect. Long-term use of Metformin may lead to vitamin B12 deficiency in some patients.

This tablet is indicated for the treatment of type 2 diabetes mellitus, especially in patients who require better control of both fasting and postprandial blood sugar levels.

Not suitable for patients with type 1 diabetes, diabetic ketoacidosis, or severe liver and kidney impairment. Alcohol consumption should be avoided. Regular monitoring of blood sugar is essential, and the medication should be taken as directed by a healthcare professional.

Store in a cool, dry place below 25°C, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation